Athersys, Inc. Receives Orphan Drug D...

Athersys, Inc. Receives Orphan Drug Designation for MultiStem in Hurler's Syndrome

There are 2 comments on the BioSpace story from Jul 10, 2012, titled Athersys, Inc. Receives Orphan Drug Designation for MultiStem in Hurler's Syndrome. In it, BioSpace reports that:

Athersys, Inc. announced today that MultiStemA , Athersys' proprietary cell therapy, has been granted orphan drug designation by the U.S. Food and Drug Administration for the treatment of Hurler's Syndrome, also known as mucopolysaccharidosis type I or MPS-I. Hurler's Syndrome is a lysosomal storage disorder that affects approximately 1 of every ... (more)

Join the discussion below, or Read more at BioSpace.

athxer

Singapore, Singapore

#1 Jul 11, 2012
any idea when a partnership for this is happening??? Don;t wish to see another dilution exercise.
athxer

Singapore, Singapore

#2 Jul 17, 2012
I'm starting to loose patience at Athersys. Whenever there's slightest bit of positive news, this damn stock will go down and remain down.

Tell me when this thread is updated:

Subscribe Now Add to my Tracker

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

Biotech Discussions

Title Updated Last By Comments
News Teva Announces Launch of Generic Zoloft (Nov '06) Jul 13 Liz 1,482
News Pfizer agrees to note addiction risks in opioid... Jul 7 BHM5267 2
News Texas Attorney General sues network marketing c... (Jul '07) Jun '16 Cynthia Gosney 5
News Zika Virus Could Spread Through Oral Sex and Ki... Jun '16 Jack 1
News Blood thinner Coumadin gets black box warning o... (Jan '07) May '16 Anita 581
News School's out: 4 tips to help your child with AD... May '16 MaryWh 2
News Bayer teams with CDC to fight Zika May '16 Go Blue Forever 1
More from around the web